Advanced Solid Tumors Clinical Trials in Denver, Colorado

6 studies are recruiting for advanced solid tumors in Denver, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

    This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tu…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute (SCRI) at HealthONE, Denver, Colorado
    Locations
    21 in total
    Run by
    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT06384352 on ClinicalTrials.gov

  2. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver, Colorado
    Locations
    20 in total
    Run by
    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

  3. A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

    This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    HealthOne Denver, Denver, Colorado
    Locations
    5 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT07372625 on ClinicalTrials.gov

  4. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The st…

    Stage
    Phase 1
    Ages
    18 to 75
    Site
    Denver Drug Development Unit, Denver, Colorado
    Locations
    38 in total
    Run by
    Shanghai Allink Biotherapeutics Co., Ltd.

    See if you can join NCT06656390 on ClinicalTrials.gov

  5. A Clinical Study of YL205 in Patients With Advanced Solid Tumors

    This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute (SCRI)- Denver, Denver, Colorado
    Locations
    43 in total
    Run by
    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT06459973 on ClinicalTrials.gov

  6. A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

    This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutat…

    Stage
    Phase 1
    Ages
    18 to 89
    Site
    Sarah Cannon Research Institute at HealthOne, Denver, Colorado
    Locations
    10 in total
    Run by
    Eikon Therapeutics

    See if you can join NCT06907043 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.